文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

针对放射性复发前列腺癌的局灶挽救性立体定向体部放疗1期试验

A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
PubMed 文献 · Pract Radiat Oncol · 2023-07-11

NCT03253744为1期试验,在局部放射性复发前列腺癌患者中确定图像引导局灶挽救性立体定向体部放疗的最大耐受剂量。3个剂量水平为5次分割40 Gy、42.5 Gy、45 Gy,按3+3设计递增。最大耐受剂量为40 Gy/5次,24个月生化无进展生存率100%,最常见临床显著毒性为晚期≥2级泌尿生殖毒性。

要点

  • 最大耐受剂量为5次分割40 Gy(DL1)。
  • 24个月生化无进展生存率100%,33个月时1例生化失败。
  • 最常见临床显著毒性为晚期≥2级泌尿生殖毒性。

核心结论

  • 针对孤立性前列腺内放射性复发的局灶挽救性立体定向体部放疗的最大耐受剂量为5次分割40 Gy。
  • 该剂量下24个月生化无进展生存率为100%,研究结束后33个月时出现1例失败。
  • 最常见的临床显著毒性为晚期≥2级泌尿生殖毒性。

研究设计与样本

  • NCT03253744为1期试验,旨在确定图像引导局灶挽救性立体定向体部放疗的最大耐受剂量。
  • 设3个剂量水平:DL1为40 Gy、DL2为42.5 Gy、DL3为45 Gy,均分5次、间隔≥48小时给予。
  • 处方剂量给予磁共振和前列腺特异性膜抗原影像所定义的肿瘤体积。
  • 剂量递增采用3+3设计,并在最大耐受剂量处进行3例患者扩展。
  • 毒性按常见不良事件评价标准第5.0版评分至立体定向体部放疗完成后2年。

主要发现

  • 2018年8月至2022年5月,8例患者接受挽救性局灶立体定向体部放疗,中位随访35个月。
  • DL1未观察到剂量限制性毒性效应。
  • DL2入组2例患者并发生3级泌尿生殖毒性,促使降剂量并在最大耐受剂量(DL1)处扩展6例。
  • 最常见毒性为≥2级泌尿生殖毒性,仅见1例2级胃肠道毒性,无≥3级胃肠道毒性。
  • 1例患者在33个月时出现生化失败(前列腺特异性抗原最低值+2.0)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: NCT03253744 was a phase 1 trial to identify the maximum tolerated dose (MTD) of image-guided, focal, salvage stereotactic body radiation therapy (SBRT) for patients with locally radiorecurrent prostate cancer. Additional objectives included biochemical control and imaging response. METHODS AND MATERIALS: The trial design included 3 dose levels (DLs): 40 Gy (DL1), 42.5 Gy (DL2), and 45 Gy (DL3) in 5 fractions delivered ≥48 hours apart. The prescription dose was delivered to the magnetic resonance- and prostate-specific membrane antigen imaging-defined tumor volume. Dose escalation followed a 3+3 design with a 3-patient expansion at the MTD. Toxicities were scored until 2 years after completion of SBRT using Common Terminology Criteria for Adverse Events, version 5.0, criteria. Escalation was halted if 2 dose-limiting toxicities occurred, defined as any persistent (>4 days) grade 3 toxicity occurring within the first 3 weeks after SBRT and any grade 3 genitourinary (GU) or grade 4 gastrointestinal (GI) toxicity thereafter. RESULTS: Between August 2018 and May 2022, 8 patients underwent salvage focal SBRT, with a median follow-up of 35 months. No dose-limiting toxic effects were observed on DL1. Two patients were enrolled in DL2 and experienced grade 3 GU toxicities, prompting de-escalation and expansion (n = 6) at the MTD (DL1). The most common toxicities observed were grade ≥2 GU toxicities, with only a single grade 2 GI toxicity and no grade ≥3 GI toxicities. One patient experienced biochemical failure (prostate-specific antigen nadir + 2.0) at 33 months. CONCLUSIONS: The MTD for focal salvage SBRT for isolated intraprostatic radiorecurrence was 40 Gy in 5 fractions, producing a 100% 24-month biochemical progression free survival, with 1 poststudy failure at 33 months. The most frequent clinically significant toxicity was late grade ≥2 GU toxicity.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Patel KR, Rydzewski NR, Schott E, et al. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer. Pract Radiat Oncol. 2023. PMID: 37442430. doi:10.1016/j.prro.2023.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。